www.oncotarget.com Oncotarget, 2018, Vol. 9, (No. 74), pp: 33912-33930 Research Paper Estrogen receptor-beta is a potential target for triple negative breast cancer treatment David Austin1, Nalo Hamilton2, Yahya Elshimali1, Richard Pietras3,4, Yanyuan Wu1 and Jaydutt Vadgama1,3,4 1Department of Medicine, Division of Cancer Research and Training, Charles Drew University School of Medicine and Science, Los Angeles, CA 90059, USA 2UCLA School of Nursing, University of California at Los Angeles, Los Angeles, CA 90095, USA 3UCLA Johnson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA 90095, USA 4UCLA David Geffen School of Medicine, Department of Medicine, Division of Hematology-Oncology, University of California at Los Angeles, Los Angeles, CA 90095, USA Correspondence to: Jaydutt Vadgama, email:
[email protected] Keywords: estrogen receptor-beta; triple negative breast cancer; insulin-like growth factor 2; DPN; estrogen receptor-beta signaling Received: December 06, 2017 Accepted: July 12, 2018 Published: September 21, 2018 Copyright: Austin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Triple Negative breast cancer (TNBC) is a subtype of breast cancer that lacks the expression of estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2. TNBC accounts for 15-20% of all breast cancer cases but accounts for over 50% of mortality. We propose that Estrogen receptor-beta (ERβ) and IGF2 play a significant role in the pathogenesis of TNBCs, and could be important targets for future therapy.